STAT+: An Anavex study spin job sullies an otherwise spectacular Alzheimer’s conference
Anavex Life Sciences said Thursday that its experimental treatment for Alzheimer’s disease slowed the rate of cognitive decline in a clinical trial — but only by changing the study’s primary efficacy goals, omitting patients from the analysis, randomly altering data, making basic math errors, whistling past safety concerns, and using nonsensical statistical tests.
Put all those issues aside, and Anavex’s drug performed wonderfully. In fantasy land.
Continue to STAT+ to read the full story…
